Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells

Inflamm Res. 2005 May;54(5):194-203. doi: 10.1007/s00011-005-1343-z.

Abstract

Objective: Our aim was to study how different SERMs modulate the inflammatory responses induced by lipopolysaccharide (LPS) or unmethylated CpG-oligonucleotides in mouse and rat microglial cells.

Materials and methods: Inflammatory responses of mouse N9 microglial cells and rat primary hippocampal microglia to lipopolysaccharide (LPS) exposure were recorded by the secretion of nitric oxide (NO) and cytokine IL-6 in two models where SERM was added either 24 h before LPS addition or simultaneously or even after the LPS exposure. The responses of 17beta-estradiol, tamoxifen, raloxifene and ICI 182.780 were compared. Responses were recorded by ELISA, Northern and EMSA assays.

Results: SERMs but not 17beta-estradiol induced a significant, concentration-dependent anti-inflammatory response both in rat primary microglial cells and in mouse N9 microglial cells. The response was observed both in NO and IL-6 secretion as well as in total IL-6 mRNA expression. We have recently observed that histone deacetylase (HDAC) inhibitors can potentiate the LPS-induced inflammatory response. Raloxifene and tamoxifen inhibited the potentiation of LPS response induced by trichostatin A, an HDAC inhibitor, in N9 microglia. A SERM-induced anti-inflammatory response was observed in acute models where SERM was added simultaneously or even up to 6 h later than LPS exposure. In contrast, the pretreatment of N9 microglia with tamoxifen or raloxifene for 30 h before LPS exposure did not provide any protection against the LPS response. We also observed that the raloxifene-induced protection in N9 microglia was connected to a decline of LPS-induced DNA binding activity of AP-1 but not that of NF-kappaB transcription factors.

Conclusions: Our results show that tamoxifen, raloxifene and ICI 182.780 induce an anti-inflammatory response in acute models of mouse and rat microglial cells. It seems that this response is not estrogen receptor-mediated but, probably, is attributable to some SERM-induced modulation of LPS-activated pro-inflammatory signalling cascades.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Astrocytes / cytology
  • Blotting, Northern
  • Cell Proliferation
  • Cells, Cultured
  • CpG Islands
  • DNA / metabolism
  • Dose-Response Relationship, Drug
  • Down-Regulation
  • Enzyme-Linked Immunosorbent Assay
  • Estradiol / analogs & derivatives
  • Estradiol / metabolism
  • Estradiol / pharmacology
  • Fulvestrant
  • Hippocampus / cytology
  • Histone Deacetylase Inhibitors
  • Histone Deacetylases / metabolism
  • Humans
  • Inflammation / drug therapy*
  • Interleukin-6 / blood
  • Interleukin-6 / metabolism
  • L-Lactate Dehydrogenase / metabolism
  • Lipopolysaccharides / metabolism
  • Mice
  • Microglia / metabolism
  • Microglia / pathology*
  • Nitric Oxide / metabolism
  • Oligonucleotides / metabolism
  • Protein Binding
  • RNA, Messenger / metabolism
  • Raloxifene Hydrochloride / pharmacology
  • Rats
  • Rats, Wistar
  • Selective Estrogen Receptor Modulators / pharmacology*
  • Tamoxifen / pharmacology
  • Time Factors

Substances

  • Anti-Inflammatory Agents
  • Histone Deacetylase Inhibitors
  • Interleukin-6
  • Lipopolysaccharides
  • Oligonucleotides
  • RNA, Messenger
  • Selective Estrogen Receptor Modulators
  • Tamoxifen
  • Fulvestrant
  • Nitric Oxide
  • Raloxifene Hydrochloride
  • Estradiol
  • DNA
  • L-Lactate Dehydrogenase
  • Histone Deacetylases